Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
View Patent ↗This disclosure is directed to the use of sequentially applied topical therapy with a lower dosage strength imiquimod composition and photodynamic therapy for treating actinic keratosis, wherein the photodynamic therapy is administered subsequent to the topical therapy with the imiquimod composition. In some embodiments, the imiquimod composition comprises from about 1% (w/w) to about 4.25% (w/w) imiquimod.
1. A method of treating actinic keratosis (AK) in a subject in need thereof, the method comprising:
topically applying to a treatment area on the subject an imiquimod composition comprising from about 1% (w/w) to about 4.25% (w/w) imiquimod, wherein the step of applying the imiquimod composition to the treatment area comprises a first treatment and a second treatment period, wherein the first and second treatment periods are separated by a non-treatment period and wherein each of the first treatment period, the second treatment period, and the non-treatment period is for a length of time of up to three weeks; and
subsequent to the topical application of the imiquimod composition, administering photodynamic therapy to the treatment area or to an AK lesion in the treatment area, wherein the photodynamic therapy treatment is administered within four weeks after completion of the imiquimod treatment; thereby treating AK in the subject.
2. The method of claim 1 , wherein applying the imiquimod composition to the treatment area comprises a first two-week treatment period and a second two-week treatment period, wherein the first and second treatment periods are separated by a two-week non-treatment period.
3. The method of claim 1 , wherein applying the imiquimod composition to the treatment area comprises a first three-week treatment period and a second three-week treatment period, wherein the first and second treatment periods are separated by a three-week non-treatment period.
4. The method of claim 1 , wherein the imiquimod composition is administered once daily.
5. The method of claim 1 , wherein the imiquimod composition comprises imiquimod in an amount of about 2.5% (w/w).
6. The method of claim 1 , wherein the imiquimod composition comprises imiquimod in an amount of about 3.75% (w/w).
7. The method of claim 1 , wherein the imiquimod composition is applied as a field-directed treatment.
8. The method of claim 1 , wherein the photodynamic therapy comprises:
administering a topical formulation comprising a photoreactive compound to the treatment area or to an AK lesion in the treatment area; and
irradiating the treatment area of the subject with a light having a wavelength corresponding to the characteristic light absorption wavelength of the photoreactive compound.
9. The method of claim 8 , wherein the photoreactive compound is aminolevulinic acid (ALA).
10. The method of claim 1 , wherein the treatment area is the face or scalp.
11. The method of claim 1 , wherein the AK lesion is a clinically visible, palpable, non-palpable, or non-hypertrophic lesion.
12. The method of claim 1 , wherein the photodynamic therapy treatment is administered within 14 days after completion of the imiquimod treatment.
13. The method of claim 1 , wherein the method results in the clearance of at least 75% of the baseline AK lesions in the subject.
14. The method of claim 13 , wherein the method results in the complete clearance of AK lesions in the subject.
15. A method of treating actinic keratosis (AK) in a subject in need thereof, the method comprising:
topically applying to a treatment area on the subject a composition comprising imiquimod in an amount of about 2.5% (w/w) or about 3.75% (w/w) over a first two-week treatment period;
topically applying to the treatment area on the subject the imiquimod composition over a second two-week treatment period, wherein the first two-week treatment period and the second two-week treatment period are separated by a two-week non-treatment period; and
subsequent to the application of the imiquimod composition, administering photodynamic therapy to the treatment area or to an AK lesion in the treatment area, wherein the photodynamic therapy treatment is administered within four weeks after completion of the imiquimod treatment; thereby treating AK in the subject.